header-logo header-logo

23 September 2016
Issue: 7715 / Categories: Case law , Law digest , In Court
printer mail-detail

EU

Sun Pharmaceuticals Industries Ltd and another company v European Commission T-460/13, [2016] All ER (D) 52 (Sep)

The General Court of the European Union dismissed the application by Sun Pharmaceuticals Industries Ltd (formerly Ranbaxy Laboratories Ltd) and Ranbaxy (UK) Ltd for annulment in part of Commission Decision C(2013) 3803 final of 19 June 2013 relating to a proceeding under Art 101 of the Treaty on the Functioning of the European Union and Art 53 of the European Economic Area Agreement and for reduction of the amount of the fine imposed on those companies by that decision. The General Court held that none of the pleas in law relied on by them in support of their application was well founded.

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

Switalskis—five appointments

Switalskis—five appointments

Firm expands national abuse compensation team

Mathys & Squire—nine promotions

Mathys & Squire—nine promotions

IP firm announces new partners and senior promotions across UK offices

Carey Olsen—five promotions

Carey Olsen—five promotions

Carey Olsen promotes five lawyers to the partnership

NEWS
Executors may be overlooking billions of pounds in estate assets hidden in forgotten investments and misplaced share certificates
Britain’s booming non-surgical cosmetics market is operating in what some critics describe as a regulatory ‘Wild West’
Family contact disputes are becoming an increasingly prominent feature of Court of Protection litigation
Material obtained through US discovery applications may have a much longer legal life than many litigants realise
English courts are developing a distinctly practical approach to sanctions disputes arising from Russia’s invasion of Ukraine
back-to-top-scroll